Demyelinating Diseases
12 cases on disease-modifying therapy selection in multiple sclerosis, NMOSD, and MOGAD, PML/JC virus risk stratification, and acute relapse management — choose a case below to open its full multi-voice debate.
Fourteen lesions, two relapses, an EDSS of 2.0 — and no treatment yet, which makes today the opening move rather than a correction. Start with the strongest drug, or start moderate and escalate when she breaks through? The registries favor the first. The trials built to settle it have not reported.
Three years of nothing — no relapse, no lesion, no change on exam — and a laboratory value that has nearly doubled. The number tracks a brain infection, not his disease. Spacing the infusions out lowers it without giving up the drug. Whether that is risk management or postponement is what the group has to decide.
A scheduling collision, not a clinical one: her seventh ocrelizumab infusion and a travel vaccine series land in the same month. Moving the infusion buys a better antibody response and costs a schedule that has not needed touching in three years. Whether that trade is worth making turns on which vaccines, against what.
Her resting heart rate is 56. The threshold that triggers first-dose cardiac observation for ozanimod is 55. She clears it by one beat — while taking a beta-blocker, which the trials behind that threshold largely did not enroll. The group can monitor around the problem, or remove it.
Two courses, four years ago, and nothing since — that was the whole design. One new lesion now has to be read against a drug built to keep working after it stops being given, which makes it genuinely unclear whether the effect is lapsing or this is the background noise any therapy produces.
Aggressive early MS, one failed first-line drug, and the strongest agent on the shelf — which the label says to hold back until two drugs have failed. Severity argues for reaching now; the label argues for one more trial first. Only her next scan can tell the group which read was right, and only after it commits.
One approved drug exists for his diagnosis, and the trial that won it enrolled patients up to 55 with active inflammation on their scans. He is 61, ten years in, with two consecutive quiet MRIs. Whether the approval describes him is a different question from whether it covers him.
Twelve years on rituximab without a relapse or a lesion, and now two pneumonias and an IgG below the floor. The trial built for exactly this question came back ambiguous by design — it missed non-inferiority by half a percentage point, on an endpoint made mostly of lesions nobody felt.
Two women in the same clinic, both hoping to conceive inside six months, both on a drug that complicates it — in opposite directions. One drug can plausibly continue through pregnancy. The other has to be actively driven out of the body, and nobody has started the clock.
Her insurer denied the targeted biologic once, on paperwork rather than clinical grounds, and the appeal has no timeline. She has had two attacks in six months and one has already cost her part of a visual field. What protects her while the appeal moves is the whole question.
A full five-day course of high-dose IV steroids has moved nothing — her EDSS is exactly where it started. Plasma exchange has one randomized trial behind it in this precise situation, and that trial enrolled twenty-two patients. Trying steroids again has none. Neither option is well evidenced; only one has a clock attached.
His first attack is effectively over — near-complete visual recovery, three weeks out. What is unresolved is whether there will be a second, and no test can say. Treating now protects the children who would have relapsed and commits the rest to years of therapy they never needed.